Daré Bioscience, Inc. DARE

Is dare will get any benefit from abortion pill ban ?

Accomplishments:

License Agreement with Organon to Commercialize XACIATOTM
Ovaprene® IDE Approval for Pivotal Contraceptive Efficacy Study
Positive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1
Three Additional Portfolio Programs (DARE-PDM1, DARE-GML and grant-funded DARE-LBT)
2023 Anticipated Milestones:

XACIATO™ First Commercial Sale
Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Topline Data
Ovaprene Pivotal Contraceptive Efficacy Study Initiaton
DARE-PDM1 Phase 1 Study Topline Data
IND and Clinical Study Initiation Activities for DARE-VVA1 and DARE-HRT1
SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2022 and provided a company update.

“Daré announced a number of positive developments related to our existing portfolio since the beginning of 2022 which serve to benefit all of our stakeholders. We entered into an exclusive global license agreement with Organon for commercialization of our first FDA-approved product, XACIATO™. We completed two Phase 1/2 clinical studies in Australia and announced positive topline data for both. We received FDA approval of our IDE application for Ovaprene, allowing us to conduct a single arm, open-label pivotal contraceptive efficacy study and we hosted an investigator meeting. Finally, we completed subject screening for our exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% for female sexual arousal disorder and are targeting the second quarter of 2023 to announce topline data. We seek to continue the progress made over the past fifteen months by moving these candidates forward in development in 2023 and 2024,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.

Analyst Forecast
According to 12 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is $6.12, which is an increase of 494.18% from the latest price.

Price Target
$6.12
(494.18% upside)
Analyst Consensus: Buy

Strong​Sell
Sell
Hold
Buy
Strong​Buy
0
5
10

https://newsfilter.io/a/69057eda52df36f61fe657567b58284e

Xaciato is a Vaginal Anti-infectives class drug manufactured by ORGANON. The average counter price of Xaciato is $202.99 per 1, 5GM of 2% Gel, but you can pay only $151.22 for 1, 5gm of 2% Tube of generic Xaciato with a SingleCare prescription drug discount card to use the generic Xaciato coupon.
https://www.singlecare.com › xaciato
Xaciato Coupons 2023: Up to 80% Discount - SingleCare

Dare Bioscience Stock (NASDAQ:DARE), Analyst Ratings, Price Targets, Predictions
Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1
Buy
Highest Price Target1
$7.00
Lowest Price Target1
$6.00
Consensus Price Target1
$6.50
Analyst Rating Summary1
Buy Overweight Hold Underweight Sell 2 0 0 0 0

Analyst Forecast
According to 10 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 521.88% from the latest price.

Price Target
$5.1
(521.88% upside)
Analyst Consensus: Buy

Strong​Sell
Sell
Hold
Buy
Strong​Buy
0
5
10

Daré Bioscience, Inc. Announces Global Licensing Rights To The Novel Antimicrobial Glycerol Monolaurate For Vaginal Health
Mentioned: DARE
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it has entered into a license agreement with Hennepin Life Sciences LLC under which Daré acquired the exclusive global rights to develop and commercialize treatments delivering the novel antimicrobial glycerol monolaurate (GML) intravaginally for a variety of vaginal health conditions including bacterial, fungal, and viral infections.

DARÉ BIOSCIENCE CONSENSUS RATING AND PRICE TARGET (2022)How MarketBeat Calculates Price Target and Consensus Rating
CONSENSUS ANALYST RATING
BUY
Based on 3 Analyst Ratings
CONSENSUS ANALYST PRICE TARGET
$9.00
620.00% Upside
High Prediction $17.00
Average Prediction $9.00
Low Prediction $4.00

Analyst Forecast
According to 10 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 4.85, which is an increase of 340.91% from the latest price.

Price Target
$4.85
(340.91% upside)
Analyst Consensus: Buy
Chart

Bar chart with 5 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from 0 to 7.

Strong​Sell
Sell
Hold
Buy
Strong​Buy
0
5
10